- Conditions
- Hepatitis C Infection
- Interventions
- MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2)
- Biological · Drug
- Lead sponsor
- MassBiologics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced May 22, 2026, 3:51 AM EDT